The myeloproliferative neoplasms (MPNs) are chronic hematological malignancies originating at the level of the pluripotent hematopoietic stem cell (HSC). This unique assembly of both laboratory and clinical MPN investigators coupled with the infrastructure to conduct independent, investigator-initiated, multicenter, trials has proven to be rewarding over the last 10 years of continuous NCI-funding and is poised to continue to further evolve. Keeping in mind the constructive reviewer comments, we have concentrated our clinical efforts into a stronger and more nimble consortium of 9 core clinical sites based solely in North America with established centers of excellence in MPN. The new application for Project 4 (formerly Project 6) is focused on myelofibrosis (MF) the MPN with the most limited survival and the clinical translation of mechanism based therapeutics derived from disease targets identified in Projects 1-3. An initial wave of early phase, single agent clinical trials (MPN-RC 116-118) will be conducted in years 1-3 and then three innovative combination therapy trials derived from supportive pre-clinical data and single agent tolerability and signal of activity will be pursued in years 3-5 (MPN-RC 119-123). Additionally, primary MPN tissue will be acquired through the MPN-RC tissue procurement protocol (Core B) and genomically characterized (Core D) from patients seen at all sites for distribution to Projects 1-3. Each trial will also have study schedule-specific, protocol driven, biomarkers to determine 1) effect on MPN HSC burden through mutational and cytogenetic analysis; 2) confirmation of proposed therapeutic mechanism of action through drug specific pharmacodynamic studies; 3) restoration of normal bone marrow microenvironment through histomorphologic analysis and cytokine expression profiles. The overarching goal of Project 4 is to test agents and innovative approaches that alone or in combination delete the MF HSC and favorably modify the MF-supporting microenvironment, thereby, altering the natural history of MF and improving patient outcome.
The specific aims i nclude 1) Annually obtain peripheral blood from MF patients in order to provide molecularly characterized tissue specimens that will be utilized for the investigations planned in Projects 1-3; 2) Conduct early phase clinical trials years 1-3 utilizing agents targeting the MPN HSC that have mechanistic rationales originating from Projects 1-3; 3) Evaluate therapeutic agents in early phase clinical trials years 1-3 that can interrupt the MF HSC supporting tumor microenvironments and, thereby, restore a bone marrow niche favoring normal hematopoiesis; 4) Utilize agents from Phase I/II trials associated with Aims 2 and 3 that can be tested in combination therapy approaches in years 3-5. The close interaction among the scientific projects, biostatistical, administrative, tissue bank, and biomarker cores with Project 4 embodies the true potential for translational research in MF that only the MPN-RC can provide.

Public Health Relevance

The overall goal of this project is to directly translate therapies originating from therapeutic targets identified from scientific Projects 1-3 into novel treatment strategies targeting the myeloproliferative neoplasm (MPN) hematopoietic stem cell (HSC) and the supportive microenvironmental abnormalities in patients with myelofibrosis (MF). Such therapies will be evaluated in investigator-initiated, early developmental phase, clinical trials with agents derived from the scientific Projects (1-3) and designed to deplete the MPN HSC through direct anti- clonal activity and modification of the impaired microenvironment, thereby favorably altering the natural history of disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA108671-10A1
Application #
9416775
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179
Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184

Showing the most recent 10 out of 195 publications